Levoketoconazole

Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year Expects fourth quarter and full year 2025 Recorlev® net revenue of $45 million and $139 million, respectively Full-year 2025 financial results and 2026 outlook planned for March 2, 2026 CHICAGO--(BUSINESS WIRE)--Jan. 8, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our fourth quarter performance capped off a truly transformative 2025. Recorlev® delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year,” said John Shannon, Chief Executive Officer. “When combined with the stellar contributions of Gvoke® and Keveyis®, we expect total revenue of approximately $292 million, exceeding the high end of our full-year 2025 guidance.” Shannon continued, “As we look ahead, we are incredibly excited about the opportunities before us. We enter the year with strong commercial momentum, supported by a robust balance sheet and a clear, disciplined strategy to fuel sustained, long-term, rapid growth across the business." Preliminary Full Year 2025 Highlights Recorlev® ended the year with approximately 700 patients on therapy, and our commercial expansion was executed according to plan. Gvoke® grew revenue more than 13% compared to the prior year. Keveyis® finished the year with a growing patient base and a greater number of patients on therapy compared to year-end 2024. Delivered positive Adjusted EBITDA in every quarter. Strengthened Xeris’ intellectual property portfolio with a new Orange Book-listed U.S. patent for Recorlev® and a composition of matter patent for XP-8121, reinforcing long-term protection across both commercial and pipeline assets. Presented long-term financial targets and a clear strategic vision to drive sustained growth and value creation during the Company’s first Analyst and Investor Day. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the financial outlook for 2025, including quarterly product revenue, projections regarding total revenue, patients on therapy, positive adjusted EBITDA, company performance in 2026, the potential for growth of revenue, the company’s ability to continue on its current growth trajectory, including its ability to fuel sustained long-term, rapid growth across its business, the market, demand and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline (including XP-8121), the timing of the release of its financial results and outlook, and other statements containing the words “achieve,” “anticipate,” “continue,” “expect,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results (including revenue and sales in the near- and long-term), performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission (SEC), the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ SEC filings are not the only risks the company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. You are encouraged to read its filings with the SEC, available at www.sec.gov and www.xerispharma.com, for a discussion of these and other risks and uncertainties. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. Xeris is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260108889727/en/ Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

库欣综合征：隐匿的“激素炸弹” 近日，30岁的李先生因体重飙升来到华中科技大学同济医学院附属同济医院的健康体重管理门诊寻求帮助。医生在检查时发现其腹部及腋窝下有异常紫纹，这个细节成为诊断关键。进一步检查显示，李先生的皮质醇水平远超正常值。最终，他被确诊为库欣综合征，而非单纯肥胖。 “若未及时诊断，他可能会出现严重的骨质疏松、泌尿系结石、高血压、低钾血症和糖尿病。”该院内分泌科主任杨雁回忆，通过垂体磁共振检查发现，李先生的垂体上长有微小肿瘤。将肿瘤切除后，李先生体重逐渐下降，病情缓解。 杨雁介绍，库欣综合征被称作隐匿的“激素炸弹”，是因体内糖皮质激素长期过量导致的临床综合征。其核心是各种病因导致肾上腺皮质分泌过多皮质醇，又称皮质醇增多症。这种疾病的特点是皮质醇异常升高引发全身性损害，患者会出现向心性肥胖、皮肤紫纹、“水牛背”等典型体征，同时伴随多种代谢异常，如高血压、糖尿病、骨质疏松等，以及神经精神症状。 北京协和医院内分泌科主任医师卢琳介绍，库欣综合征缺乏国内的流行病学调查数据，但从发表的文献来看，该病的全球年发病率为每百万人2至5人，患病率为每百万人40至70人。无论按哪个国家的罕见病标准，该病都属于典型的罕见病。库欣综合征病因复杂多样，包括垂体源性库欣综合征（垂体瘤导致的库欣病）、异位神经内分泌肿瘤导致的异位ACTH（促肾上腺皮质激素）综合征和肾上腺肿瘤或者结节性增生。 卢琳介绍，过高的皮质醇随血液循环，对人体各个系统都有严重伤害，除了多种代谢异常以外，对患者病情威胁最突出的是抑制机体的免疫功能，导致患者易发生机会性感染。“在我院就诊的重症库欣综合征患者经常合并各种罕见病原体感染。这些机会性感染治疗效果差，在高皮质醇状态下病情难以得到控制，是威胁患者生命的严重并发症之一。此外，急性心血管疾病和难以控制的高血糖也是威胁患者生命安全的重要并发症。”卢琳说。 比疾病本身更可怕的是诊断难题。库欣综合征临床表现复杂多样，极易被误诊。卢琳表示，患者常从儿科、妇产科、心内科、感染科、心理科等多个科室转诊而来。她说：“有的孩子因身材矮小被当作普通矮小症治疗，有的女性因月经不调或不孕被当作普通不孕症诊治，还有患者因情绪异常在心理医学科治疗效果不好才确诊。其根本原因在于致病肿瘤往往微小且隐匿，即便用先进的CT（计算机断层扫描）、磁共振甚至全身PET-CT（正电子发射计算机断层显像）检查，仍有部分患者无法找到病灶。” 杨雁也有同样的感受，她说：“罕见病的狡猾之处在于它不会照着教科书生病。有的患者仅表现为反复血钾浓度低，有的则以‘磕碰后淤青难消’为唯一症状，这些非典型表现让很多医生难以识别。” 用药困境：可选少、价格高、可及性差 对于无法手术或手术失败、术后复发的库欣综合征患者，药物治疗成为唯一选择，但现有药物的现状不尽如人意。卢琳坦言，治疗库欣综合征的药物长期面临“可选少、价格高、可及性差”的困境。 卢琳介绍，目前国内上市且适应证包含库欣综合征的药物仅有磷酸奥唑司他，其副作用相对较小、疗效明确，但价格昂贵，未被纳入医保。其他可用药物的情况同样不容乐观。米托坦是通过罕见病药物政策引进的药品，主要适应证为肾上腺皮质癌，在北京协和医院需通过超说明书用药备案才能用于库欣综合征治疗。然而，该药物副作用较大，需同时关注肝功能和胃肠道不良反应，且费用高昂。还有一些在国外上市的药物，如左旋酮康唑等，在国内还属于不可及药品，患者无法正常使用。 药物可及性差不仅体现在供应端，还存在地域差异。卢琳曾专门调查各地普惠政策对磷酸奥唑司他的覆盖情况，发现部分偏远地区覆盖最好但人口有限，很多经济发达地区反而未将其纳入。 沉重的用药负担让很多患者及其家庭陷入绝境。卢琳透露，多数库欣综合征患者家庭经济条件有限，很多患者不能早期得到诊断，辗转就诊花费很多，患者因病往往丧失劳动能力，最终可能因病致贫。 保障体系：初步建成但仍有短板 库欣综合征患者的困境是我国罕见病群体保障现状的一个缩影。中国药科大学国际医药商学院副院长茅宁莹介绍，我国罕见病保障体系建设已取得显著进展，2018年发布的《第一批罕见病目录》纳入121种疾病，2023年发布的《第二批罕见病目录》新增86种，目录病种总数扩展至207种，为保障工作提供了基础依据。 在保障机制方面，我国已构建起基本医保、大病保险、医疗救助、慈善援助等多层次保障体系。茅宁莹表示，截至2024年底，涉及68种罕见病的126种药物已被纳入医保。全国199款惠民保产品中，近3年超50%已纳入罕见病用药，部分产品还将医保目录外的高值罕见病药品纳入报销范畴。 但这一体系仍存在诸多短板，目前仍有一些疾病或其治疗药物未被纳入我国罕见病目录或医保目录。首都医科大学附属北京天坛医院医保办主任张韬指出，针对罕见病患者需求，现有社会保障体系仍需完善。张韬说：“罕见病不一定发生在贫困人群中。现有医疗救助体系针对贫困群体和存在因病致贫可能的人群的保障力度还不是太高。” 保障覆盖的广度与深度不足是突出问题。茅宁莹透露，截至2024年底，仍有针对58种罕见病的65种药物未被纳入医保，其中33种罕见病的全部治疗药物都未进入医保目录。在纳入罕见病目录的207种疾病中，有30种疾病在欧美已获批药物，但国内尚无对应药物上市；8种疾病对应药物已在国内上市，但未获批相应罕见病适应证。 专项保障机制缺失导致高值药物难以覆盖。张韬表示，罕见病药物往往价格极高，且患病人群少，单纯依靠基本医保难以承担；而在商业保险方面，健康险种类不同，保障疾病范围和金额也不一样，患者即便购买了商业保险也可能无法理赔。天津大学药物科学与技术学院党委书记、教授吴晶也指出，未进入医保目录的罕见病药物年治疗费用多在一两百万元，成为社会保障体系的堵点和痛点。 罕见病药物的高研发成本与低患者基数，使其成为保障体系建设的关键障碍。吴晶表示，与普通药物不同，罕见病药物研发成本高、患者基数小，需通过较高定价才能让企业收回成本，否则会大大降低企业研发积极性。 为解决这一问题，国际上普遍采用提高支付意愿的方式进行报销决策。吴晶介绍，与普通药物相比，我国对罕见病药物的支付意愿会适当提高，以平衡企业研发回报与患者可及性。吴晶说：“价格杠杆可引导企业研发方向，避免低水平重复。对已饱和领域的药物减少研发回报，可将资源引导至临床急需的领域，如无药可治的罕见病。” 由于罕见病患者样本量小，临床试验数据有限，真实世界数据可弥补罕见病药物评价证据不足的问题。吴晶介绍，通过罕见病患者组织收集的真实世界数据，可精准描绘患者疾病症状、临床路径和医疗资源消耗，包括发病年龄、误诊次数、治疗方案、疾病进展、医疗费用等关键信息，为药物经济学评价提供基础数据支撑。 多方发力：构建精准可持续的保障体系 针对罕见病保障存在的问题，多位专家从不同角度提出建议，聚焦诊断、用药、支付等关键环节，推动体系不断完善。 在诊断能力提升方面，需强化基层识别能力与跨院协作。杨雁建议建立“异常体征筛查机制”，患者出现2至3个罕见病特殊症状即启动排查流程，同时组建罕见病联盟实现全生命周期管理。卢琳则认为，可以通过制订临床指南、开展学术交流、建立绿色转诊通道等方式，提升全国医疗机构的诊疗规范度。“比如，可以通过库欣综合征人脸识别系统，利用患者典型外貌特征辅助基层医生识别，同时加强继续教育强化医生认知。”卢琳说。 在药物可及性改善方面，需兼顾研发激励与引进加速。茅宁莹建议采取“双轮驱动”策略，一方面通过税收优惠、市场独占期等政策激励本土企业研发，关注基因治疗等前沿技术；另一方面优化境外药品审评审批流程，缩短上市时间差。 在支付保障优化方面，需构建多元共付格局。茅宁莹建议建立独立的罕见病专项基金，作为高值药品支付的核心手段，形成“基本医保保基本、专项基金攻难关、商保慈善作补充”的多元支付体系。吴晶则强调，需完善药物经济学评价工具与决策标准，建立符合中国国情的健康相关生命质量测量量表，确保评价结果更贴合我国患者需求和医疗实践。张韬认为，基本医保作为基本保障，需首先保证可持续性，同时也要体现公益性。“建议在充分评估的基础上，将基本医保基金分出一部分专门用于罕见病支付，或强制所有健康险纳入罕见病药物，通过分散风险的方式实现‘众人拾柴火焰高’的社会保障效果。”张韬说。 在政策协同与机制创新方面，需强化跨部门联动与制度保障。茅宁莹建议建立部门间常态化沟通衔接机制，优化诊断与医疗资源布局，减轻患者异地就医负担，同时探索从“目录制”向“定义制”的转变。卢琳建议建立来自一线临床医生的罕见病建议通道，真实和科学地界定罕见病范围，让库欣综合征这一真正意义上的罕见病早日进入国家罕见病目录，加强药企、医疗人员对该病的关注和研究，进而真正惠及患者。 文：吴刚 吴风港 编辑：王依依 审核：孙梦 喜欢就告诉我们您“在看”